JNJ-40411813 - CAS 1127498-03-6
Catalog number: 1127498-03-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H25ClN2O
Molecular Weight:
344.88
COA:
Inquire
Targets:
mGluR
Description:
JNJ-40411813 is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 nM.
Purity:
>98%
Synonyms:
JNJ-40411813; JNJ 40411813; JNJ40411813; ADX71149; ADX 71149; ADX-71149.
MSDS:
Inquire
InChIKey:
HYOGJHCDLQSAHX-UHFFFAOYSA-N
InChI:
InChI=1S/C20H25ClN2O/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17H,2-3,9-10,12-14H2,1H3
Canonical SMILES:
CCCCN1C=CC(=C(C1=O)Cl)N2CCC(CC2)C3=CC=CC=C3
1.Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor.
Cid JM1, Tresadern G, Duvey G, Lütjens R, Finn T, Rocher JP, Poli S, Vega JA, de Lucas AI, Matesanz E, Linares ML, Andrés JI, Alcazar J, Alonso JM, Macdonald GJ, Oehlrich D, Lavreysen H, Ahnaou A, Drinkenburg W, Mackie C, Pype S, Gallacher D, Trabanco AA. J Med Chem. 2014 Aug 14;57(15):6495-512. doi: 10.1021/jm500496m. Epub 2014 Jul 28.
We previously reported the discovery of 4-aryl-substituted pyridones with mGlu2 PAM activity starting from the HTS hit 5. In this article, we describe a different exploration from 5 that led to the discovery of a novel subseries of phenylpiperidine-substituted pyridones. The optimization strategy involved the introduction of different spacers between the pyridone core and the phenyl ring of 5. The fine tuning of metabolism and hERG followed by differentiation of advanced leads that were identified on the basis of PK profiles and in vivo potency converged on lead compound 36 (JNJ-40411813). Full in vitro and in vivo profiles indicate that 36 displayed an optimal interplay between potency, selectivity, favorable ADMET/PK and cardiovascular safety profile, and central EEG activity. Compound 36 has been investigated in the clinic for schizophrenia and anxious depression disorders.
2.Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies.
Salih H1, Anghelescu I1, Kezic I1, Sinha V1, Hoeben E1, Van Nueten L1, De Smedt H1, De Boer P2. J Psychopharmacol. 2015 Apr;29(4):414-25. doi: 10.1177/0269881115573403. Epub 2015 Mar 3.
Metabotropic glutamate receptor-2 positive allosteric modulator, JNJ-40411813 (ADX71149), was characterised for clinical effects in healthy volunteers in two phase-1 studies. In study 1, healthy men received 50-, 100-, 150- or 225 mg and women received 100 mg JNJ-40411813 (n=6, each cohort) or placebo (n=2, each cohort) twice daily for seven days; smoking men (n=30) received placebo twice daily on days 1-7, 100 mg JNJ-40411813 (n=20) or placebo (n=10) on days 8-14. In study 2, healthy men received intravenous 0.005 mg/kg S(+) ketamine over 60 min at 3 (n=24; cohort 1), 12 h (n=8; cohort 3), and 24 h (n=8; cohort 2) after a single oral dose of 500 mg JNJ-40411813 or placebo. The pharmacokinetics and effects of JNJ-40411813 on cognition and subjective awareness were evaluated. Plasma JNJ-40411813 exposure was dose-dependent, t max ranged from 3-4 h and t 1/2 19.4-34.2 h across the dose levels. JNJ-40411813 significantly (p=0.02) reduced continuity of attention score (150 mg dose) and ameliorated smoking withdrawal-induced changes in power of attention and quality of episodic memory versus placebo.
3.Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813.
Lavreysen H1, Langlois X1, Donck LV1, Nuñez JM2, Pype S1, Lütjens R3, Megens A1. Pharmacol Res Perspect. 2015 Mar;3(2):e00097. doi: 10.1002/prp2.97. Epub 2015 Jan 30.
JNJ-40411813/ADX71149 (1-butyl-3-chloro-4-(4-phenylpiperidin-1-yl) pyridin-2(1H)-one) is a positive allosteric modulator (PAM) of the mGlu2 receptor, which also displays 5-Hydroxytryptamine (5HT2A) antagonism after administration in rodents due to a rodent-specific metabolite. JNJ-40411813 was compared with the orthosteric mGlu2/3 agonist LY404039 (4-amino-2-thiabicyclo [3.1.0] hexane-4,6-dicarboxylic acid 2,2-dioxide), the selective mGlu2 PAM JNJ-42153605 (3-(cyclopropylmethyl)-7-(4-phenylpiperidin-1-yl)-8-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridine) and the 5HT2A antagonist ritanserin in rodent models for antipsychotic activity and potential side effects, attempting to differentiate between the various compounds and mechanisms of action. In mice, JNJ-40411813, JNJ-42153605, and LY404039 inhibited spontaneous locomotion and phencyclidine- and scopolamine-induced but not d-amphetamine-induced hyperlocomotion; the 5HT2A antagonist ritanserin inhibited only spontaneous locomotion and phencyclidine-induced hyperlocomotion.
4.Translational neurophysiological markers for activity of the metabotropic glutamate receptor (mGluR2) modulator JNJ-40411813: Sleep EEG correlates in rodents and healthy men.
Ahnaou A1, de Boer P2, Lavreysen H3, Huysmans H3, Sinha V4, Raeymaekers L3, Van De Casteele T5, Cid JM6, Van Nueten L2, Macdonald GJ3, Kemp JA3, Drinkenburg WH3. Neuropharmacology. 2016 Apr;103:290-305. doi: 10.1016/j.neuropharm.2015.11.031. Epub 2015 Dec 12.
Alterations in rapid eye movement sleep (REM) have been suggested as valid translational efficacy markers: activation of the metabotropic glutamate receptor 2 (mGluR2) was shown to increase REM latency and to decrease REM duration. The present paper addresses the effects on vigilance states of the mGluR2 positive allosteric modulator (PAM) JNJ-40411813 at different circadian times in rats and after afternoon dosing in humans. Due to its dual mGluR2 PAM/serotonin 2A (5-HT2A) receptor antagonism in rodents, mGlu2R specificity of effects was studied in wild-type (WT) and mGluR2 (-/-) mice. 5-HT2A receptor occupancy was determined in humans using positron emission tomography (PET). Tolerance development was examined in rats after chronic dosing. EEG oscillations and network connectivity were assessed using multi-channel EEG. In rats, JNJ-40411813 increased deep sleep time and latency of REM onset but reduced REM time when administered 2 h after 'lights on' (CT2): this was sustained after chronic dosing.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mGluR Products


CAS 56-85-9 L-Glutamine

L-Glutamine
(CAS: 56-85-9)

L-Glutamine is one of the 20 amino acids encoded by the standard genetic code.

CAS 71301-82-1 (S)-3-Hydroxyphenylglycine

(S)-3-Hydroxyphenylglycine
(CAS: 71301-82-1)

(S)-3-Hydroxyphenylglycine is an agonist at group I metabotropic glutamate receptors (mGlu1) with no effect at mGlu2 or mGlu4.

CAS 170846-89-6 E4CPG

E4CPG
(CAS: 170846-89-6)

E4CPG is a group I/group II metabotropic glutamate receptor antagonist with higher potency than (RS)-MCPG.

CAS 55136-48-6 (S)-3-Carboxy-4-hydroxyphenylglycine

(S)-3-Carboxy-4-hydroxyphenylglycine
(CAS: 55136-48-6)

(S)-3-Carboxy-4-hydroxyphenylglycine has been found to be a mixed group II mGlu agonist as well as group I metabotropic glutamate receptor antagonist.

CAS 1382481-79-9 ML 289

ML 289
(CAS: 1382481-79-9)

ML-289 is a negative allosteric modulator of mGlu3 with IC50 value of 0.66 μM. It displays 15-fold selectivity over mGlu2 and inactivity against mGlu5.1.

CAS 59-00-7 Xanthurenic acid

Xanthurenic acid
(CAS: 59-00-7)

Xanthurenic acid acts as an endogenous Group II metabotropic glutamate receptor (mGluR2 and mGluR3) agonist in transfected HEK293 cells at nanomolar concentrati...

LY 341495 disodium salt

Disodium salt of LY 341495. LY 341495 is a group II metabotropic glutamate receptor antagonist.

CAS 802906-73-6 RG7090

RG7090
(CAS: 802906-73-6)

RG7090 is a negative modulator of metabotropic glutamate receptor subtype 5 (mGluR5; GRM5).

Chemical Structure

CAS 1127498-03-6 JNJ-40411813

Quick Inquiry

Verification code

Featured Items